Narendran Rajesh C, Duarte Rui V, Valyi Andrea, Eldabe Sam
Department of Pain and Anaesthesia, The James Cook University Hospital, Middlesbrough, UK.
College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
BMJ Open. 2015 Jun 30;5(6):e007517. doi: 10.1136/bmjopen-2014-007517.
The aim of this study was to evaluate changes in the uptake of intrathecal baclofen (ITB) following commissioning of this therapy by the National Health Service (NHS) England in April 2013. The specific objectives of this study were: (i) to explore the gap between the need for and the actual provision of ITB services; and (ii) to compare England figures with other European countries with comparable data available.
Data for ITB -related procedures were obtained from the Hospital Episode Statistics (HES) database from 2009/2010 to 2013/2014.
Patients receiving ITB for the management of spasticity.
The available data for implantation of ITB from 2009/2010 to 2013/2014 for the treatment of spasticity due to varied aetiologies show that there has not been an increase in uptake of this therapy. The estimated need for this treatment based on the incidence and prevalence of conditions susceptible to ITB therapy is between 4.6 and 5.7 per million population. Our analysis of the data available from the HES database showed that the actual number of implants is around 3.0 per million population. The same period 2009-2014 has seen an increase in the delivery of other neuromodulation techniques including spinal cord stimulation, deep brain stimulation and sacral nerve stimulation.
There is a considerable gap between the need for and provision of ITB figures nationally. Additionally, within the same area, we have observed important differences in the ITB service delivery between the various trusts. The reasons for this can be multifactorial, including individual experience and opinions, organisational structures, resource and financial limitations. Further research analysing the efficacy and cost-effectiveness of this treatment in the UK might inform the development of Technology Appraisal Guidance for ITB, potentially leading to an improvement in service provision.
本研究旨在评估2013年4月英国国家医疗服务体系(NHS)英格兰地区启用鞘内注射巴氯芬(ITB)疗法后该疗法使用情况的变化。本研究的具体目标为:(i)探究ITB服务的需求与实际提供之间的差距;(ii)将英格兰的数据与其他有可比数据的欧洲国家进行比较。
与ITB相关程序的数据取自2009/2010至2013/2014年的医院事件统计(HES)数据库。
接受ITB治疗痉挛的患者。
2009/2010至2013/2014年因各种病因治疗痉挛而植入ITB的现有数据表明,该疗法的使用量并未增加。基于易受ITB疗法影响的疾病的发病率和患病率,估计该治疗的需求量为每百万人口4.6至5.7例。我们对HES数据库中可用数据的分析表明,实际植入数量约为每百万人口3.0例。2009 - 2014年期间其他神经调节技术的应用有所增加,包括脊髓刺激、深部脑刺激和骶神经刺激。
全国范围内ITB的需求与提供数据之间存在相当大的差距。此外,在同一地区,我们观察到各信托机构之间ITB服务提供存在重要差异。其原因可能是多方面的,包括个人经验和观点、组织结构、资源和资金限制。进一步分析该治疗在英国的疗效和成本效益的研究可能为ITB的技术评估指南的制定提供参考,有可能改善服务提供情况。